INARI MEDICAL, INC.

(NARI)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
71.14 USD   +2.74%
06/24BTIG Adjusts Inari Medical's Price Target to $100 from $130, Keeps Buy Rating
MT
06/21Inari Medical's Shares Rise After Piper Sandler Initiates Coverage
MT
06/21Piper Sandler Starts Inari Medical at Overweight With $100 Price Target
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

SVB Leerink Adjusts Inari Medical's Price Target to $95 from $85, Maintains Outperform Rating

02/24/2022 | 12:44pm EDT


© MT Newswires 2022
All news about INARI MEDICAL, INC.
06/24BTIG Adjusts Inari Medical's Price Target to $100 from $130, Keeps Buy Rating
MT
06/21Inari Medical's Shares Rise After Piper Sandler Initiates Coverage
MT
06/21Piper Sandler Starts Inari Medical at Overweight With $100 Price Target
MT
06/17INSIDER SELL : Inari Medical
MT
06/09INSIDER SELL : Inari Medical
MT
06/09Certain Options of Inari Medical, Inc. are subject to a Lock-Up Agreement Ending on 9-J..
CI
06/09Certain Restricted Stock Units of Inari Medical, Inc. are subject to a Lock-Up Agreemen..
CI
06/09Certain Common Stock of Inari Medical, Inc. are subject to a Lock-Up Agreement Ending o..
CI
06/08INSIDER SELL : Inari Medical
MT
06/07OKAMI MEDICAL ANNOUNCES FDA 510(k) CLEARANCE OF THE LOBO-7 and LOBO-9 VASCULAR OCCLUDER..
PR
More news
Analyst Recommendations on INARI MEDICAL, INC.
More recommendations
Financials (USD)
Sales 2022 365 M - -
Net income 2022 -38,5 M - -
Net cash 2022 316 M - -
P/E ratio 2022 -95,6x
Yield 2022 -
Capitalization 3 779 M 3 779 M -
EV / Sales 2022 9,49x
EV / Sales 2023 7,94x
Nbr of Employees 800
Free-Float 84,9%
Chart INARI MEDICAL, INC.
Duration : Period :
Inari Medical, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INARI MEDICAL, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 71,14 $
Average target price 105,00 $
Spread / Average Target 47,6%
EPS Revisions
Managers and Directors
William H. Hoffman President, Chief Executive Officer & Director
Mitchell C. Hill Chief Financial Officer
Don B. Milder Chairman
Thomas Tu Chief Medical Officer
Tara Dunn VP-Clinical Affairs & Market Development
Sector and Competitors
1st jan.Capi. (M$)
INARI MEDICAL, INC.-22.06%3 779
NOVOCURE LIMITED0.69%7 907
MASIMO CORPORATION-53.68%7 693
SHOCKWAVE MEDICAL, INC.10.86%7 076
GETINGE AB-41.69%6 197
PENUMBRA, INC.-54.15%4 964